The importance of understanding the controls governing commitment and differentiation of hematopoietic stem cells (HSCs) to specific lineages is underscored by the fact that a block in differentiation is a hallmark of acute leukemias. Acute myeloid leukemia (AML) accounts for most acute leukemias in adults. The transcription factor PU.1 regulates nearly every known myeloid gene and is absolutely required for normal myeloid development. PU.1 is expressed in stem cells and up-regulated early during myeloid and lymphoid commitment. The importance of understanding how PU.1 is regulated is emphasized by studies indicating that altered expression of PU.1 can induce changes in hematopoietic lineage development and dysregulation leads to leukemia. Thus, the overall goal of this continuation proposal is to carry on our studies of how PU.1 is regulated. In the next funding period, we plan to continue previous efforts to study how transcription factors regulate PU.1 by binding to the PU.1 upstream regulatory element (URE). In addition, we will extend these studies to the role of proper regulation of PU.1 on HSC function. These studies will further our understanding of commitment of normal hematopoietic precursors to the myeloid lineage. As such, they are relevant to understanding the block in normal myeloid maturation from blasts to mature myeloid cells in AML.
It is critical to understand how hematopoietic stem cells either self-renew or undergo differentiation to mature blood elements, because this process of differentiation is blocked in Acute Myeloid Leukemia (AML), the most common form of acute leukemias in adults. PU.1 is a transcription factor, meaning a gene whose product turns other genes on and off, and the levels of PU.1 are critical in both normal blood development and in leukemia. By studying how PU.1 is expressed in stem cells and other blood cells, we seek to understand basic mechanisms which will aid in our understanding of how leukemia develops, and ultimately for development of novel therapies based on these findings.
|Bararia, Deepak; Kwok, Hui Si; Welner, Robert S et al. (2016) Acetylation of C/EBP? inhibits its granulopoietic function. Nat Commun 7:10968|
|Gerloff, D; Grundler, R; Wurm, A A et al. (2015) NF-?B/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia 29:535-47|
|Bräuer-Hartmann, Daniela; Hartmann, Jens-Uwe; Wurm, Alexander Arthur et al. (2015) PML/RAR?-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Res 75:3411-24|
|Welner, Robert S; Amabile, Giovanni; Bararia, Deepak et al. (2015) Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 27:671-81|
|Aikawa, Yukiko; Yamagata, Kazutsune; Katsumoto, Takuo et al. (2015) Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells. Cancer Sci 106:227-36|
|Ye, Min; Zhang, Hong; Yang, Henry et al. (2015) Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell 17:611-23|
|Mishima, Yuta; Wang, Changshan; Miyagi, Satoru et al. (2014) Histone acetylation mediated by Brd1 is crucial for Cd8 gene activation during early thymocyte development. Nat Commun 5:5872|
|Liss, Adam; Ooi, Chia-Huey; Zjablovskaja, Polina et al. (2014) The gene signature in CCAAT-enhancer-binding protein ? dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors. Haematologica 99:697-705|
|Staber, Philipp B; Zhang, Pu; Ye, Min et al. (2014) The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. Blood 124:2391-9|
|Zhou, J; Wu, J; Li, B et al. (2014) PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. Leukemia 28:1436-48|
Showing the most recent 10 out of 26 publications